Galapagos collaborates with Charley's Fund, Nash Avery Foundation to develop SARM candidate drug for Duchenne muscular dystrophy

17-Sep-2009 - Belgium

Galapagos NV, Charley's Fund Inc. and the Nash Avery Foundation announced that they will collaborate to investigate the potential effectiveness of Galapagos' SARM candidate drug, G100192, in treating Duchenne muscular dystrophy. G100192 is an orally-available small molecule therapeutic, which has demonstrated successful Proof of Concept in pre-clinical studies for cachexia (the loss of weight and muscle mass).

Charley's Fund and the Nash Avery Foundation will support the costs of pre-clinical studies to assess the potential effectiveness of G100192 in treating Duchenne muscular dystrophy. While investigating this new indication, Galapagos will continue to develop the SARM therapeutic for cachexia, and plans to initiate a Phase I clinical trial in healthy volunteers in the beginning of 2010.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance